Loading
Create a way for a charity or university to get a cheap old drug officially approved for a new cancer use, with a few years of protection on that use so trial costs can be recovered without high prices.
A dedicated regulatory pathway for new oncology indications of off-patent drugs, accessible to non-commercial sponsors, with three to five years of indication-specific data exclusivity that can be assigned to a non-profit or public body. The exclusivity is for reimbursement of the indication rather than for the molecule, so generic supply for existing uses is unaffected; a modest per-indication payment from payers repays the trial. Without this, academic repurposing results cannot reach the label and remain off-label and unevenly used.
Shares Automatic offer of shelved cancer assets to non-profits after two years, A non-profit pharmaceutical company for the cancers markets ignore.
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares A non-profit pharmaceutical company for the cancers markets ignore, Incentives reward me-too drugs and marginal gains.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.